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Perﬂuorooctanesulfonate(PFOS)isaperﬂuoroalkylacid(PFAA)andapersistentenvironmentalcontaminantfoundinthetissues
of humans and wildlife. Although blood levels of PFOS have begun to decline, health concerns remain because of the long half-life
of PFOS in humans. Like other PFAAs, such as, perﬂuorooctanoic acid (PFOA), PFOS is an activator of peroxisome proliferator-
activated receptor-alpha (PPARα) and exhibits hepatocarcinogenic potential in rodents. PFOS is also a developmental toxicant
in rodents where, unlike PFOA, its mode of action is independent of PPARα. Wild-type (WT) and PPARα-null (Null) mice
were dosed with 0, 3, or 10mg/kg/day PFOS for 7 days. Animals were euthanized, livers weighed, and liver samples collected
for histology and preparation of total RNA. Gene proﬁling was conducted using Aﬀymetrix 430 2 microarrays. In WT mice, PFOS
induced changes that were characteristic of PPARα transactivation including regulation of genes associated with lipid metabolism,
peroxisome biogenesis, proteasome activation, and inﬂammation. PPARα-independent changes were indicated in both WT and
Null mice by altered expression of genes related to lipid metabolism, inﬂammation, and xenobiotic metabolism. Such results are
similar to studies done with PFOA and are consistent with modest activation of the constitutive androstane receptor (CAR), and
possibly PPARγ and/or PPARβ/δ. Unique treatment-related eﬀects were also found in Null mice including altered expression of
genes associated with ribosome biogenesis, oxidative phosphorylation, and cholesterol biosynthesis. Of interest was up-regulation
of Cyp7a1, a gene which is under the control of various transcription regulators. Hence, in addition to its ability to modestly
activate PPARα, PFOS induces a variety of PPARα-independent eﬀects as well.
1.Introduction
Perﬂuoroalkyl acids (PFAAs) are stable man-made perﬂu-
orinated organic molecules that have been utilized since
the 1950s in the manufacture of a variety of industrial
a n dc o m m e r c i a lp r o d u c t ss u c ha sﬁ r eﬁ g h t i n gf o a m s ,
ﬂuoropolymers for the automobile and aerospace industry,
paper food packaging, stain-resistant coatings for carpet
and fabric, cosmetics, insecticides, lubricants, and nonstick
coatings for cookware. One such PFAA, perﬂuorooctane
sulfonate (PFOS), was identiﬁed nearly a decade ago as a
persistent organic pollutant which could also be found in
the tissues of wildlife throughout the globe [2]. Since that
time, a number of perﬂuorinated sulfonic and carboxylic2 PPAR Research
Table 1: Average body weight and liver weight of control and PFOS-treated mice on the day of tissue collection.1
Dose group
WT Null
Body weight Total liver weight Relative liver weight Body weight Total liver weight Relative liver weight
0mg/kg 28.3±.0 1.21±0.17 0.043±0.014 30.3±1.3 1.04±0.06 0.034±0.003
3mg/kg 26.2±1.5 1.12±0.18 0.043±0.002 28.0±1.2 1.20±0.05 0.043±0.001
10mg/kg 31.4±1.5 1.98±0.11∗ 0.062±0.003∗ 30.2±1.7 1.48±0.16∗ 0.049±0.012∗
1Data are mean±SE, ∗Signiﬁcantly diﬀerent than control (P ≤ .05).
Table 2: Number of fully annotated genes altered by PFOS, PFOA1, or Wy-14,6431 in wild-type and PPARα-null mice (P ≤ .0025)
2.
PFOS PFOA Wy 14,643
3mg/kg/day 10mg/kg/day 3mg/kg 50mg/kg/day
Wild-type 81 906 879 902
PPARα-null 630 808 176 10
1From Rosen et al. (2008), 2 Based on Ingenuity Pathways Analysis database.
acids of varying chain length have been shown to be
persistent and ubiquitous environmental contaminants.
Some of these compounds are also commonly identiﬁed
in the tissues of humans and wildlife with the 8-carbon
PFAAs, PFOS and perﬂuorooctanoic acid (PFOA), being
the most frequently reported in biomonitoring studies
(for reviews, see [3, 4]). In recent years, blood levels
of PFOS and PFOA have gradually begun to decline
in the general population [5, 6]. This is due in part to
a production phase out of PFOS by its principal U.S.
manufacturer as well as a commitment by key manufacturers
of perﬂuorinated chemicals to reduce the product content
and emissions of PFOA, and related chemistries, under
the EPA 2010/2015 PFOA Stewardship Program (http://
www.epa.gov/oppt/pfoa/pubs/stewardship/index.html).
Nevertheless, certain PFAAs are likely to remain of concern
for years to come due to their environmental persistence and
long biological-half lives [7].
PFOS and PFOA are associated with toxicity in labo-
ratory animals at blood levels that are approximately 2-
3 orders of magnitude above those normally observed in
humans. This includes hepatomegaly and liver tumors in
rats and mice as well as pancreatic and testicular tumors
in rats (for review see [4]). Teratogenic activity has also
been observed in rats and mice, however, such ﬁndings
have been limited to maternally toxic doses of PFOS [8],
whereas, both PFOS and PFOA have been shown to alter
growth and viability of rodent neonates at lower doses [4].
Recent epidemiologic data suggests that typical exposures
to these compounds may alter fetal growth and fertility in
humans [9–13]. These studies, however, lack consistency
with regard to either compound activity or measured end
point; therefore, alternative explanations for such ﬁndings
have been suggested [14]. Moreover, a recent study of
individuals exposed to PFOA in drinking water at levels that
were approximately two orders of magnitude higher than the
general population did not show an eﬀect on average birth
weight or the incidence of low birth weight infants [15].
The mode of action related to PFAA toxicity in rodents is
not fully understood. As a class of chemicals, PFAAs activate
peroxisome proliferator-activated receptor alpha (PPARα)
[16–18], and chronic activation of this nuclear receptor is
thought to be responsible for the liver enlargement and
hepatic tumor induction found in laboratory animals [19].
However, activation of PPARα is not thought to be a relevant
mode of action for hepatic tumor formation in humans [20–
25], although this assumption has been challenged recently
[26]. This does not, however, rule out the possibility that
c e r t a i nP F A A sc o u l dh a v ea na d v e r s ee ﬀect on development
since activation of PPARα has been shown to play a role
in PFOA-induced neonatal loss in mice [27]. In addition,
PPARα-independent modes of action are also likely for var-
ious PFAAs. Unlike prototypical activators of PPARα,s u c h
as, the ﬁbrate class of pharmaceuticals, PFOA can induce
fatty liver in wild-type mice [28]. PFOA can also induce
hepatomegalyinPPARα-nullmice[27,29,30]andis capable
of activating the constitutive androstane receptor (CAR)
[31–33]. Moreover, PFOS can induce neonatal toxicity in the
PPARα-null mouse [34].
In the current study, we used global gene expression
proﬁling to assess the transcriptional changes induced by
PFOS in the liver of wild-type and PPARα-null mice. The
data were compared to results previously published by our
groupforPFOAandWy-14,643,acommonlyusedagonistof
PPARα [1]. Our goal was to identify both PPARα-dependent
and independent changes induced by PFOS.
2.MaterialsandMethods
2.1. Animals and Dosing. Studies were approved by the
U.S. EPA ORD/NHEERL Institutional Animal Care and Use
Committee. The facilities and procedures used followed the
recommendations of the 1996 NRC “Guide for the Care and
Use of Laboratory Animals,” the Animal Welfare Act, and the
Public Health Service Policy on the Humane Care and Use of
Laboratory Animals.
PPARα-null (Null) mice (129S4/SvJae-Pparatm1Gonz/J,
stock no. 003580) and wild-type (WT) mice (129S1/SvlmJ,
stock no. 002448) were initially purchased from The Jackson
Laboratory (Bar Harbor, ME) and maintained as an inbredPPAR Research 3
Table 3: Average fold change for genes related to lipid metabolism in wild-type and PPARα-null male mice following a seven-day exposure
to Wy-14,6431,P F O A 1, or PFOS.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
ACAA1 acetyl-CoA
acyltransferase 1 113868 1.89 2.92 1.61 2.10∗∗ 1.22 1.37 1.53∗
ACAA1B acetyl-CoA
acyltransferase 1B 235674 2.38 2.70 1.49 1.40∗∗ 3.00 1.09 1.19∗
ACAD10 acyl-CoA dehydrogenase,
member 10 71985 1.51 2.39 −1.18 1.38∗∗ −1.01 1.05 1.20∗
ACADL acyl-CoA dehydrogenase,
long chain 11363 3.03 2.86 1.40 1.68∗∗ 2.50 1.34 1.59∗∗
ACADM acyl-CoA dehydrogenase,
C-4 to C-12 11364 1.70 1.30 1.21 1.31∗∗ 1.06 1.11 1.10
ACADS acyl-CoA dehydrogenase,
C-2 to C-3 66885 1.03 1.52 1.22 1.31∗ −1.13 −1.12 −1.08
ACADSB acyl-CoA dehydrogenase,
short/branched 66885 −1.56 −1.64 −1.04 −1.39∗∗ −1.26 1.00 −1.23
ACADVL acyl-CoA dehydrogenase,
very long chain 11370 1.92 1.80 1.44 1.49∗∗ 1.16 1.04 1.12
ACAT1 acetyl-CoA
acetyltransferase 1 101446 −1.01 1.10 1.45 1.36∗ −1.55 −1.05 −1.17
ACAT2 acetyl-CoA
acetyltransferase 2 110460 2.59 1.68 1.14 1.34∗ 1.26 1.58 1.69∗∗
ACOT1 acyl-CoA thioesterase 1 26897 19.48 73.06 3.27 6.82∗∗ 2.95 1.53 2.02
ACOT3 acyl-CoA thioesterase 3 171281 2.55 32.83 2.42 6.41∗∗ −1.59 1.46 1.86
ACOT2 acyl-CoA thioesterase 2 171210 3.83 19.29 1.91 7.32∗∗ 1.78 1.25 1.52
ACOX1 acyl-CoA oxidase 1 11430 5.65 7.17 1.23 1.49∗∗ 1.51 1.30 1.29∗∗
ACSL1 acyl-CoA synthetase long-
chain member1 14081 1.34 2.36 1.28 1.36∗∗ 1.01 1.31 1.30
ACSL3 acyl-CoA synthetase long-
chain member3 74205 2.25 1.90 1.28 1.69∗∗ 1.11 1.77 1.63
ACSL4 acyl-CoA synthetase long-
chain member4 50790 1.95 2.00 1.03 1.42∗ 1.51 1.34 1.29
ACSL5 acyl-CoA synthetase long-
chain member5 433256 3.06 2.76 1.24 1.31∗∗ 1.38 1.23 1.28
ALDH1A1 aldehyde dehydrogenase 1,
member A1 11668 1.56 1.59 1.07 1.12∗∗ 1.22 1.16 1.17
ALDH1A7 aldehyde dehydrogenase 1,
A7 26358 1.83 1.86 1.12 1.24∗ 1.55 1.26 1.35
ALDH3A2 aldehyde dehydrogenase 3,
member A2 11671 3.65 7.72 2.10 3.80∗∗ 2.30 1.73 2.20∗∗
ALDH9A1 aldehyde dehydrogenase 9,
member A1 56752 1.80 1.91 1.27 1.50∗∗ 1.21 1.05 1.11∗
CPT1B
carnitine
palmitoyltransferase
1B (muscle)
12896 2.29 1.50 1.23 2.69∗∗ −1.00 1.13 1.11
CPT2 carnitine
palmitoyltransferase II 12896 1.33 2.54 1.58 2.03∗∗ 1.44 1.15 1.34
CYP4A14 cytochrome P450, 4, a,
polypeptide 14 13119 75.38 103.48 11.26 12.28∗∗ 12.75 −1.09 2.22
DCI dodecenoyl-CoA
delta isomerase 13177 2.91 4.55 1.90 2.38∗∗ 1.99 1.04 1.38∗
ECH1 enoyl CoA hydratase 1,
peroxisomal 51798 3.27 5.23 1.93 2.49∗∗ 2.10 1.16 1.394 PPAR Research
Table 3: Continued.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
EHHADH enoyl-CoA, hydratase 74147 27.89 22.11 2.37 4.34∗∗ 1.37 1.32 1.52∗
FABP1 fatty acid binding protein
1, liver 14080 −1.27 1.02 1.11 1.24∗∗ 1.25 −1.09 −1.23
HADHA Trifunctional protein,
alpha unit 97212 2.13 2.95 1.37 1.65∗∗ 1.01 1.06 1.02
HADHB Trifunctional protein, beta
unit 231086 2.33 3.43 1.37 1.60∗∗ 1.08 −1.15 −1.28∗
HSD17B4 hydroxysteroid (17-beta)
dehydrogenase4 15488 2.03 2.56 1.34 1.45∗∗ −1.13 1.12 1.20∗
SLC27A1 solute carrier 27, member
1 26457 9.14 8.22 −1.02 1.14∗ −1.57 1.04 1.04
SLC27A2 solute carrier 27,
member 2 26458 1.48 1.80 1.19 1.16∗∗ 1.33 1.10 1.05
SLC27A4 solute carrier 27,
member 4 26569 1.87 1.91 1.04 1.31∗∗ −1.03 1.09 1.07
1From Rosen et al. (2008),
∗Signiﬁcantly diﬀerent than control (P ≤ .03),
∗∗Signiﬁcantly diﬀerent than control (P ≤ .0025)
(a) (b)
(c) (d)
Figure 1: Hematoxylin-and eosin-stained tissue sections from control and PFOS treated mice. Control WT and Null mice are shown in
panels (a) and (b), respectively. WT and null mice treated with 10mg/kg/day PFOS are shown in panels (c) and (d), respectively. Vacuole
formation was observed in sections from treated WT mice, and in sections from control and treated Null mice. Mice exposed to 3mg/kg/day
PFOS were similar to controls (data not shown). Bar=50μm.
colony on the 129/Sv background at the U.S. EPA, Research
Triangle Park, NC. Animals were housed 5 per cage and
allowed to acclimate for a period of one week prior to the
conduct of the study. Food (LabDiet 5P00 Prolab RHM3000,
PMI Nutrition International, St. Louis, MO) and municipal
tap water were provided ad libitum. Animal facilities were
controlled for temperature (20−24◦C), relative humidity
(40%−60%), and kept under a 12hr light-dark cycle. The
experimental design matched that of our previous study
[1]. PPARα-null and wild-type male mice at 6−9 months
o fa g ew e r ed o s e db yg a v a g ef o r7c o n s e c u t i v ed a y sw i t h
either 0, 3, or 10mg/kg PFOS (potassium salt, catalog no.
77282, Sigma Aldrich, St, Louis, MO) in 0.5% Tween 20.
Five biological replicates consisting of individual animalsPPAR Research 5
Table 4: Average fold change for genes related to proteasome biogenesis in wild-type and PPARα-null male mice following a seven-day
exposure to Wy-14,6431,P F O A 1, or PFOS.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PSMA1 proteasome unit,
alpha type, 1 26440 1.61 1.38 1.15 1.31∗ 1.17 −1.29 −1.34
PSMA2 proteasome unit,
alpha type, 2 19166 −1.46 −1.15 1.09 1.23∗∗ −1.34 −1.20 −1.07
PSMA3 proteasome unit,
alpha type, 3 19167 1.33 1.22 1.12 1.14 1.28 −1.13 −1.17
PSMA4 proteasome unit,
alpha type, 4 26441 1.19 1.32 1.10 1.19∗ 1.01 −1.04 1.05
PSMA5 proteasome unit,
alpha type, 5 26442 1.67 1.59 1.12 1.26∗∗ 1.15 −1.12 1.09
PSMA6 proteasome unit,
alpha type, 6 26443 1.20 1.29 1.14 1.24∗∗ 1.06 −1.14 −1.06
PSMA7 proteasome unit,
alpha type, 7 26444 1.47 1.60 1.23 1.53∗∗ 1.23 −1.12 1.11
PSMB1 proteasome unit,
beta type, 1 19170 1.09 1.29 1.07 1.28∗ 1.04 −1.17 1.13∗
PSMB10 proteasome unit,
beta type, 10 19171 −1.42 −1.48 −1.25 −1.19 −1.57 −1.14 −1.21∗∗
PSMB2 proteasome unit,
beta type, 2 26445 1.33 1.48 1.05 1.31∗∗ 1.02 −1.20 1.05
PSMB3 proteasome unit,
beta type, 3 26446 1.22 1.47 1.21 1.36∗∗ 1.04 −1.37 −1.20
PSMB4 proteasome unit,
beta type, 4 19172 1.59 1.65 1.27 1.55∗∗ 1.22 −1.12 1.09
PSMB5 proteasome unit,
beta type, 5 19173 1.34 1.74 1.04 1.24∗∗ 1.02 −1.15 1.03
PSMB6 proteasome unit,
beta type, 6 19175 1.54 1.83 1.08 1.24∗ 1.19 −1.23 −1.09
PSMB7 proteasome unit,
beta type, 7 19177 1.46 1.33 1.07 1.15∗∗ 1.13 −1.17 −1.09
PSMB8 proteasome unit,
beta type, 8 16913 −1.61 −2.00 −1.44 −1.51 −1.38 −1.23 −1.45∗∗
PSMB9 proteasome unit,
beta type, 9 16912 1.24 −1.12 −1.31 −1.09 −1.10 −1.11 −1.30∗∗
PSMC1 proteasome 26S unit,
ATPase, 1 19179 1.44 1.00 1.19 1.15∗ 1.11 −1.06 1.01
PSMC6 proteasome 26S unit,
ATPase, 6 67089 1.18 1.21 1.09 −1.02 1.07 1.14 −1.16
PSMD1 proteasome 26S unit,
non-ATPase, 1 70247 1.20 1.22 1.15 1.25∗∗ 1.09 1.03 1.15
PSMD11 proteasome 26S unit,
non-ATPase, 11 69077 1.56 1.38 1.09 1.26∗ −1.17 1.16 1.32
PSMD12 proteasome 26S unit,
non-ATPase, 12 66997 1.34 1.27 1.10 1.14 1.20 −1.03 1.04
PSMD13 proteasome 26S unit,
non-ATPase, 13 23997 1.21 1.38 1.14 1.26∗ −1.03 −1.38 −1.42∗∗
PSMD14 proteasome 26S unit,
non-ATPase, 14 59029 −1.39 −1.42 1.17 1.31∗ 1.31 1.01 1.17
PSMD2 proteasome 26S unit,
non-ATPase, 2 21762 1.34 1.32 1.14 1.24∗ 1.10 1.09 1.30∗∗6 PPAR Research
Table 4: Continued.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PSMD3 proteasome 26S unit,
non-ATPase, 3 22123 −1.35 −1.19 1.17 1.29∗ 1.08 1.04 1.22∗
PSMD4 proteasome 26S unit,
non-ATPase, 4 19185 1.31 1.92 1.19 1.38∗∗ 1.03 −1.07 1.17∗
PSMD6 proteasome 26S unit,
non-ATPase, 6 66413 1.17 1.33 1.10 1.14∗ 1.07 −1.06 1.04
PSMD7 proteasome 26S unit,
non-ATPase, 7 17463 1.13 1.27 1.13 1.24∗ 1.02 −1.19 −1.22∗
PSMD8 proteasome 26S unit,
non-ATPase, 8 57296 1.68 1.24 1.03 1.30∗∗ 1.16 −1.15 −1.00
PSME1 proteasome activator
unit 1 19186 1.22 −1.00 −1.05 1.32∗∗ 1.27 −1.10 −1.09
VCP valosin−containing
protein 269523 1.40 1.49 1.04 1.12 1.07 1.13 1.21∗∗
1From Rosen et al. (2008),
∗Signiﬁcantly diﬀerent than control (P ≤ .03),
∗∗Signiﬁcantly diﬀerent than control (P ≤ .0025).
Table 5: Average fold change for genes related to peroxisome biogenesis in wild-type and PPARα-null male mice following a seven-day
exposure to Wy-14,6431,P F O A 1, or PFOS.
WT Null
Symbol Gene name Entrez
no.
Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PECI peroxisome D3, D2-enoyl-
CoA isomerase 23986 1.73 3.15 1.61 1.87∗∗ 1.96 1.42 1.57∗∗
PEX1 peroxisomal biogenesis
factor 1 71382 1.25 1.84 1.07 1.21∗∗ −1.02 1.10 1.14∗
PEX11A peroxisomal biogenesis
factor 11 alpha 18631 1.80 6.71 1.70 2.99∗∗ 1.04 −1.09 −1.11
PEX12 peroxisomal biogenesis
factor 12 103737 1.07 1.36 1.11 1.17∗ 1.09 1.17 1.30∗
PEX13 peroxisomal biogenesis
factor 13 72129 1.04 1.58 1.01 1.09 1.02 1.09 1.16∗
PEX14 peroxisomal biogenesis
factor 14 56273 1.06 1.24 1.03 1.25∗ 1.03 1.05 1.13
PEX16 peroxisomal biogenesis
factor 16 18633 1.51 1.44 1.13 1.33∗∗ −1.00 −1.12 −1.03
PEX19 peroxisomal biogenesis
factor 19 19298 1.61 2.25 1.19 1.36∗∗ 1.12 1.15 1.32∗∗
PEX26 peroxisomal biogenesis
factor 26 74043 −1.32 −1.86 1.01 1.26 1.01 1.29 1.10
PEX3 peroxisomal biogenesis
factor 3 56535 1.50 1.77 1.13 1.37∗∗ −1.05 1.09 1.20∗
PEX6 peroxisomal biogenesis
factor 6 224824 1.08 −1.06 1.12 1.16 1.30 −1.08 1.09
PXMP2 peroxisomal membrane
protein 2 19301 −1.22 −1.29 −1.08 −1.20∗ −1.28 −1.13 −1.06
PXMP4 peroxisomal membrane
protein 4 59038 1.62 2.09 1.61 1.62∗ 1.99 −1.03 1.01
1From Rosen et al. [1],
∗Signiﬁcantly diﬀerent than control (P ≤ .03),
∗∗Signiﬁcantly diﬀerent than control (P ≤ .0025).PPAR Research 7
Table 6: Average fold change for genes related to the inﬂammatory response in wild-type and PPARα-null male mice following a seven-day
exposure to Wy-14,6431,P F O A 1, or PFOS.
WT Null
Symbol Gene name Entrez
no.
Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
APCS amyloid P component,
serum 20219 −1.50 −2.33 −1.23 −1.28 −1.19 1.41 1.13
C1QA complement component
1QA 12259 −1.75 −1.40 −1.13 −1.17 −1.31 −1.24 −1.34∗∗
C1R complement component 1r 50909 −2.67 −1.78 −1.15 −1.23∗ −1.22 1.16 −1.17∗
C1S complement component 1s 317677 −3.73 −2.53 −1.14 −1.62∗∗ −1.52 1.06 −1.11
C2 complement component 2 12263 −2.56 −1.91 −1.37 −1.32∗ −1.18 1.10 1.11
C3 complement component 3 12266 −1.41 −1.41 −1.04 −1.04 −1.22 1.13 1.08∗
C4B complement component 4B 12268 −2.35 −2.15 −1.08 −1.28 −1.91 1.15 −1.13
C4BP complement component
4 binding prot 12269 −1.86 −1.82 −1.11 −1.19 1.02 1.39 1.13
C6 complement component 6 12274 −2.66 −1.27 −1.35 −1.08 1.90 1.12 1.06
C8A complement
component 8, alpha 230558 −3.62 −1.94 −1.17 −1.31∗ −1.17 1.19 1.04
C8B complement
component 8, beta 110382 −5.25 −2.99 −1.20 −1.60∗∗ −1.12 1.11 1.02
C8G complement
component 8, gamma 69379 −1.59 −1.35 −1.05 −1.17∗ −1.34 −1.10 −1.17∗∗
C9 complement
component 9 12279 −2.12 −2.64 −1.35 −1.58∗∗ −1.46 1.08 −1.19∗
CFB complement
factor B 14962 −1.81 −1.77 −1.07 −1.26 −1.39 1.07 −1.11
CFH complement
factor H 12628 −2.39 −2.30 −1.19 −1.62 −1.76 1.45 −1.35
CFI complement
factor I 12630 −1.63 −1.77 −1.06 −1.15 −1.06 1.12 1.04
CRP C−reactive
protein 12944 −1.33 −1.39 −1.01 −1.15∗ 1.32 1.14 1.13
CTSC cathepsin C 13032 −1.56 −2.52 1.01 −1.36 −1.96 1.04 −1.35
F10 coagulation
factor X 14058 −1.62 −1.42 −1.09 −1.13 −1.00 1.07 −1.07
F11 coagulation
factor XI 109821 −2.17 −2.68 −1.41 −2.08∗∗ −1.08 −1.08 −1.34∗
F12 coagulation
factor XII 58992 −1.22 −1.35 −1.05 −1.14 −1.21 −1.07 −1.12∗
F13B
coagulation
factor XIII,
Bp o l y p e p t i d e
14060 −1.41 −1.54 −1.11 −1.22∗∗ 1.02 1.02 −1.12
F2 coagulation
factor II (thrombin) 14061 −1.19 −1.20 −1.02 −1.13∗ −1.10 1.02 −1.02
F5 coagulation
factor V 14067 −1.78 −1.53 −1.09 −1.44∗ −1.41 1.08 −1.34∗
F7 coagulation
factor VII 14068 −2.68 −2.15 −1.09 −1.46∗∗ −1.23 1.03 −1.03
F9 coagulation
factor IX 14071 −1.42 −1.43 −1.02 −1.39∗ −1.33 1.07 −1.19
FGA ﬁbrinogen
alpha chain 14161 −1.27 −1.75 1.00 −1.12 −1.07 1.05 −1.07
FGB ﬁbrinogen
beta chain 110135 −1.32 −1.97 1.03 −1.15 −1.25 1.08 −1.078 PPAR Research
Table 6: Continued.
WT Null
Symbol Gene name Entrez
no.
Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
FGG ﬁbrinogen gamma
chain 99571 −1.14 −1.68 1.02 −1.15∗ −1.08 1.04 −1.06
KLKB1
kallikrein B,
plasma (Fletcher
factor) 1
16621 −1.58 −1.76 −1.09 −1.39∗ −1.05 −1.03 −1.18∗
LUM lumican 17022 −1.34 −1.27 1.02 −1.20∗ −1.66 1.03 −1.27
MASP1 Mannan-
binding lectin1 17174 −1.23 −1.62 −1.19 −1.18∗ 1.11 1.18 1.17∗
MBL2 Mannose-binding
lectin 2 17195 −1.77 −2.18 −1.12 −1.23∗ −1.36 −1.20 −1.28∗∗
ORM2 orosomucoid 2 18405 −1.96 −2.04 −1.26 −1.21 −1.16 1.30 1.05
PROC protein C 19123 −1.49 −1.50 −1.02 −1.13∗ −1.09 −1.01 −1.09∗
SAA1 serum amyloid
A1 20209 −3.71 −3.98 −2.75 1.04 −2.76 6.51 2.55
SAA2 serum amyloid
A2 20210 −1.75 −1.30 −1.79 −1.29 3.05 1.44 1.22
SAA4 serum amyloid
A4, constitutive 20211 −2.19 −1.45 −1.06 −1.27 −1.02 1.47 −1.05
SERPINA1 serpin peptidase
inhibitor, clade A1 20701 −3.43 −2.07 −1.03 −1.05∗∗ −1.16 1.11 −1.33
SERPINC1 serpin peptidase
inhibitor, clade C1 11905 −1.19 −1.21 −1.03 −1.08∗ −1.02 −1.04 −1.06∗
SERPIND1 serpin peptidase
inhibitor, clade D1 15160 −1.62 −1.70 −1.08 −1.25∗∗ −1.05 1.09 1.05
SERPINE1 serpin peptidase
inhibitor, clade E1 18787 1.44 9.75 1.03 1.85∗∗ 2.95 1.03 1.26∗
SERPINF2 serpin peptidase
inhibitor, clade F2 18816 −1.15 −1.87 1.01 −1.13∗ 1.02 1.12 1.05
SERPING1 serpin peptidase
inhibitor, clade G1 12258 −1.23 −1.37 −1.12 −1.13 −1.07 1.12 1.02
VWF von Willebrand
factor 22371 1.06 1.12 −1.25 1.07 −1.51 1.22 1.14
1From Rosen et al. [1],
∗Signiﬁcantly diﬀerent than control (P ≤ .03),
∗∗Signiﬁcantly diﬀerent than control (P ≤ .0025).
were included in each dose group. Dose levels were based on
unpublished data from our laboratory and reﬂect exposures
that produce hepatomegaly in adult mice without inducing
overt toxicity. Animals utilized for RT-PCR analysis were
taken from a separate set of WT and Null mice. PCR dose
groups consisted of 4 animals per group and were treated
for seven-days with either 10mg/kg/day PFOS, 3mg/kg/day
PFOA (ammonium salt, catalog no. 77262, Sigma-Aldrich)
in 0.5% Tween 20, or 50mg/kg/day Wy-14,643 (catalog no.
C7081, Sigma-Aldrich) in 0.5% methylcellulose, along with
vehicle controls. All dosing solutions were freshly prepared
each day. At the end of the dosing period, animals were
euthanized by CO2 asphyxiation and tissue collected from
the left lobe of the liver for preparation of total RNA. Tissue
prepared for histology was collected from the same group of
animals used for microarray analysis and was taken from a
section adjacent to that utilized for RNA preparation.
2.2. RNA Preparation. Collected tissue (≤50mg) was
immediately placed in 1mL RNAlater (Applied Biosys-
tems/Ambion, Austin, TX) and stored at −20◦C. RNA
preparations for microarray analysis were then completed
by homogenizing the tissue in 1mL TRI reagent (Sigma
Chemical) followed by processing through isopropanol pre-
cipitation according to the manufacturer’s instructions. The
resulting pellets were washed with 80% ethanol and resus-
pended in RNase free water (Applied Biosystems/Ambion).
Preparations were further puriﬁed by passing approximately
100μg per sample through RNeasy spin columns (Qia-
gen, Valencia, CA). RNA for PCR analysis was prepared
using the mirVANA miRNA isolation kit (Applied Biosys-
tems/Ambion) according to the manufacturer’s protocol
withoutfurtherenrichmentforsmallRNAs.Allsamplesused
in the study were quantiﬁed using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington,PPAR Research 9
Table 7: Average fold change for genes related to xenobiotic metabolism in wild-type and PPARα-null male mice following a seven-day
exposure to Wy-14,6431,P F O A 1, or PFOS.
WT Null
Symbol Gene name Entrez
no.
Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
ADH1C alcohol dehydrogenase 1C 11522 1.27 1.02 −1.00 1.02 −1.09 −1.02 −1.04
ADH5 alcohol dehydrogenase 5 11532 −1.18 1.10 1.09 −1.04 −1.02 1.11 1.14
ADH7 alcohol dehydrogenase 7 11529 −1.51 1.06 −1.01 −1.06 −1.71 −1.01 −1.01
ALDH1L1 aldehyde dehydrogenase
1L1 107747 −1.29 −1.85 −1.08 −1.18∗ −1.41 1.76 1.68∗∗
ALDH3B1 aldehyde dehydrogenase
3B1 67689 1.12 1.04 −1.11 1.04 1.48 −1.03 −1.11
CES1 carboxylesterase 1 12623 1.43 2.29 1.61 2.62∗∗ 3.15 4.80 4.84∗∗
CES2 carboxylesterase 2 234671 3.37 5.75 1.03 2.29 4.25 1.41 1.74∗
CYP1A1 cytochrome
P450,1A1 13076 1.25 −1.93 −1.05 1.08 −1.02 1.34 1.49∗∗
CYP1A2 cytochrome
P450,1A2 13077 −1.67 −1.24 −1.13 1.10 1.26 1.15 1.25∗
CYP2A4 cytochrome
P450,2A4 13087 −4.26 1.33 1.08 2.01 5.82 1.28 1.57∗∗
CYP2B10 cytochrome
P450,2B10 13088 1.31 4.39 3.50 5.92∗ 24.20 11.34 21.66∗∗
CYP2C55 cytochrome
P450,2C55 72082 1.58 21.72 1.54 8.37∗ 110.35 10.57 25.18∗∗
CYP2C37 cytochrome
P450,2C37 13096 −2.42 1.57 1.39 1.48 4.09 1.53 1.68
CYP2C38 cytochrome
P450, 2C38 13097 1.62 1.12 1.78 2.30∗∗ −1.42 −1.26 1.03
CYP2C39 cytochrome
P450, 2C39 13098 2.45 1.51 1.65 1.51 −1.42 1.11 −1.01
CYP2C50 cytochrome
P450,2C50 107141 −2.63 1.31 1.11 1.19 1.71 1.34 1.26
CYP2C54 cytochrome
P450,2C54 404195 −2.98 1.44 1.16 1.14 1.87 1.29 1.35∗∗
CYP2C70 cytochrome
P450,2C70 226105 −2.75 −4.22 −1.23 −1.68∗ −1.05 −1.05 1.04
CYP2C65 cytochrome
P450,2C65 72303 1.44 1.63 −1.93 1.98 46.78 2.28 8.63∗∗
CYP2D10 cytochrome
P450,2D10 13101 −1.47 −1.09 −1.02 −1.03 1.33 −1.00 1.02
CYP2D26 cytochrome
P450,2D26 76279 −1.17 −1.21 1.06 −1.01 −1.12 −1.03 −1.08
CYP3A11 cytochrome
P450,3A11 13112 −1.23 1.40 1.03 1.06 4.61 1.12 1.20
CYP3A41A cytochrome
P450,3A41A 53973 −2.08 1.11 1.24 1.58∗ 2.01 1.39 1.25
CYP3A25 cytochrome
P450,3A25 56388 −1.94 −1.70 1.01 −1.01 1.04 1.13 1.12
CYP3A13 cytochrome
P450,3A13 13113 −1.54 1.19 1.22 1.38∗ 1.52 1.75 1.62∗∗
EPHX1 epoxide hydrolase 1,
microsomal 13849 1.22 1.78 1.16 1.60∗ 1.82 1.33 1.59∗
EPHX2 epoxide hydrolase 2,
cytoplasmic 13850 2.25 2.34 1.45 1.67∗∗ 1.04 1.05 1.0710 PPAR Research
Table 7: Continued.
WT Null
Symbol Gene name Entrez
no.
Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
GSTA3 glutathione
S-transferase A3 14859 1.08 −1.04 1.05 1.26 1.11 1.11 1.13
GSTA4 glutathione
S-transferase A4 14860 −2.01 −1.10 −1.02 1.52 1.37 −1.20 1.36
GSTA5 glutathione
S-transferase A5 14857 −1.12 1.44 1.19 2.76∗ 2.26 1.15 2.13
GSTK1 glutathione
S-transferase kappa 1 76263 1.85 1.43 1.02 −1.04 −1.30 −1.26 −1.27
GSTM1 glutathione
S-transferase M1 14863 −2.12 −1.56 −1.51 1.77 2.54 1.18 1.97
GSTM3 glutathione
S-transferase, mu 3 14864 −1.32 1.50 1.16 2.44∗ 1.83 1.57 2.59∗
GSTM4 glutathione
S-transferase M4 14865 2.07 3.13 1.30 2.40∗ 2.48 1.40 2.63∗
GSTP1 glutathione
S-transferase pi 1 14870 −2.79 4.14 −1.16 1.00 2.87 −1.06 −1.03
GSTT2 glutathione
S-transferase theta 2 14872 1.64 2.74 1.42 1.83∗∗ 1.13 1.16 1.43∗∗
GSTT3 glutathione
S-transferase, theta 3 103140 2.10 1.13 1.41 1.61 1.77 1.30 1.85∗∗
GSTZ1 glutathione
transferase zeta 1 14874 −1.36 −1.14 −1.03 −1.08 1.01 1.03 1.01
MGST1 microsomal
glutathione S-transferase 1 56615 1.28 1.24 −1.02 1.01 1.21 1.04 1.01
MGST3 microsomal
glutathione S-transferase 3 66447 1.73 1.60 1.24 1.80∗ −1.54 −1.31 −1.06
POR P450 (cytochrome)
oxidoreductase 18984 −1.26 2.63 1.27 1.94 2.04 2.91 3.30∗∗
UGT2B17
UDP
glucuronosyltransferase
2B17
71773 −3.90 −1.13 −1.03 1.02 1.24 1.03 −1.01
UGT2B4
UDP
glucuronosyltransferase
2B4
552899 −1.37 −1.93 −1.26 −1.23∗ 1.35 1.01 1.03
UGT2B7
UDP
glucuronosyltransferase
2B7
231396 −1.19 −1.20 −1.05 −1.05 1.16 1.04 −1.00
1From Rosen et al. (2008),
∗Signiﬁcantly diﬀerent than control (P ≤ .03),
∗∗Signiﬁcantly diﬀerent than control (P ≤ .0025).
DE) and quality evaluated using a 2100 Bioanalyzer (Agilent,
Palo Alto, CA). Only samples with an RNA Integrity number
of at least 8.0 (2100 Expert software, version B.01.03) were
included in the study [35].
2.3. Histological Examination of Tissue. Following overnight
ﬁxation in Bouins ﬁxative, collected tissue was washed three
times in PBS, dehydrated to 70% ethanol, and stored at
4◦C until use. On the day of embedding, the tissue was
dehydratedthroughanethanolgradientto100%ethanoland
paraﬃn embedded using standard techniques. Five micron
sections were then prepared using a rotary microtome prior
to routine staining with hematoxylin and eosin.
2.4. Gene Proﬁling. Microarray analysis was conducted at
the U.S. EPA NHEERL Toxicogenomics Core Facility using
Aﬀymetrix GeneChip 430 2 mouse genome arrays accord-
ing to the protocols recommended by the manufacturer
(Aﬀymetrix,SantaClara,CA).Biotin-labeledcRNAwaspro-
duced from 5ug total RNA using Enzo Single-Round RNA
Ampliﬁcation and Biotin Labeling System (Cat. no. 42420-
10, Enzo Life Sciences Inc, Farmingdale, NY), quantiﬁedPPAR Research 11
Table 8: Average fold change for genes related to cholesterol biosynthesis in wild-type and PPARα-null male mice following a seven-day
exposure to Wy-14,6431,P F O A 1, or PFOS.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
CYP51 cytochrome P450,
family 51 13121 2.85 1.37 1.27 2.10∗ 1.37 2.99 1.93∗∗
FDFT1 farnesyl-diphosphate
farnesyltransferase 1 14137 2.30 1.28 1.29 1.73∗ 1.09 2.00 1.92∗∗
FDPS farnesyl diphosphate
synthase 110196 3.19 1.79 1.16 1.38 1.83 1.84 1.96∗∗
HMGCR
3-hydroxy-3-
methylglutaryl
-CoA reductase
15357 1.79 −1.08 1.19 1.97∗∗ 1.20 1.85 1.80∗
HMGCS1
3-hydroxy-3-
methylglutaryl
-CoA synthase 1
208715 6.67 1.79 1.15 1.61 −1.06 3.11 1.86∗
HMGCS2
3-hydroxy-3-
methylglutaryl
-CoA synthase 2
15360 1.17 1.54 1.28 1.34∗ 1.25 −1.08 −1.28∗
IDI1 isopentenyl-diphosphate
delta isomerase 1 319554 3.14 1.61 1.35 1.62 1.40 1.96 1.57∗
LSS lanosterol synthase 16987 1.73 1.08 1.12 1.41 −1.26 1.98 2.13∗∗
MVK mevalonate kinase 17855 1.45 −1.24 1.12 1.22 −1.02 1.57 1.52∗∗
PMVK phosphomevalonate kinase 68603 3.23 2.04 1.36 1.51∗ 1.20 1.58 1.53∗∗
SQLE squalene epoxidase 20775 3.10 1.05 1.17 1.46 1.26 2.25 1.98∗∗
1From Rosen et al. (2008), ∗Signiﬁcantly diﬀerent than control (P ≤ .03),
∗∗Signiﬁcantly diﬀerent than control (P ≤ .0025).
using an ND-1000 spectrophotometer, and evaluated on a
2100 Bioanalyzer after fragmentation. To minimize technical
day to day variation, labeling and hybridization for all sam-
ples were conducted as a single block. Following overnight
hybridization at 45◦Ci na nA ﬀymetrix Model 640 GeneChip
hybridization oven, the arrays were washed and stained
using an Aﬀymetrix 450 ﬂuidics station and scanned on an
Aﬀymetrix Model 3000 scanner. Raw data (Aﬀymetrix Cel
ﬁles) were obtained using Aﬀymetrix GeneChip Operating
Software (version 1.4). This software also provided summary
reports by which array QA metrics were evaluated including
average background, average signal, and 3 /5  expression
ratios for spike-in controls, β-actin, and GAPDH. Only
arrays of high quality based on low background levels as
well as expected 3 /5  expression ratios for the spike-in
controls, β-actin, and GAPDH were included in the study.
Data are available through the Gene Expression Omnibus
at the National Center for Biotechnology Information
(http://www.ncbi.nlm.nih.gov/geo) as accession numbers
GSE22871.
2.5. PCR Conﬁrmation of Results. Real-time PCR analysis
of selected genes was conducted using 2 micrograms of
total RNA. All samples were initially digested using 2 units
DNaseI (no. M6101, Promega Corporation, Madison, WI)
for 30min at 37◦C followed by 10min at 65◦Ci nab u ﬀer
containing 40mM Tris (pH 8.0), 10mM MgSO4,a n d1m M
CaCl2. The RNA was then quantiﬁed using a Quant-iT
RiboGreen RNA assay kit according to the manufacturer’s
protocol (no.R11490, Invitrogen Corporation, Carlsbad,
CA) and approximately 1.5ug RNA reverse transcribed
using a High Capacity cDNA Archive Kit according to the
provided protocol (no. 4322171, Applied Biosystems, Foster
City, CA). Ampliﬁcation was performed on an Applied
Biosystems model 7900HT Fast Real-Time PCR System in
duplicate using 25ng cDNA and TaqMan Universal PCR
Master Mix (no.4304437, Applied Biosystems) in a total
volume of 12μL according to the protocol supplied by the
manufacturer. Glyceraldehyde-3-phosphate dehydrogenase
(Gapdh, Entrez no. 14433), which was uniformly expressed
among all samples (cycle threshold deviation less than 0.35),
was used as an endogenous reference gene. The following
TaqMan assays (Applied Biosystems) were included in
the study: Gapdh (no. Mm99999915 g1), Srebf2 (no.
Mm01306293 m1), Ppargc1a (Mm0047183 m1), Nfe2l2
(Mm00477784 m1), Ndufa5 (Mm00471676), Lss (no.
Mm00461312 m1), Cyp4a14 (no. Mm00484132 m1),
Cyp7a1 (no. Mm00484152 m1), and Cyp2b10 (no.
Mm00456591 m1). Fold change was calculated using
the 2-ΔΔCT method of Livak and Schmittgen [36].
2.6. Data Analysis. Body and liver weight data were ana-
lyzed by strain using a one-way ANOVA. Individual treat-
ment contrasts were assessed using a Tukey Kramer HSD
test (P ≤ .05) (JMP 7.0 (SAS, Cary, NC). Microarray
data were summarized, background adjusted, and quantile12 PPAR Research
Table 9: Average fold change for genes related to oxidative phosphorylation/electron transport in wild-type and PPARα-null male mice
following a seven-day exposure to Wy-14,6431,P F O A 1, or PFOS.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
ATP5D
ATP synthase H+
transporting,
F1delta
66043 1.03 1.10 1.04 1.09 −1.17 −1.22 −1.13∗
ATP5E
ATP synthase H+
transporting,
F1epsilon
67126 −1.10 1.21 −1.00 1.03 −1.17 −1.32 −1.38∗∗
ATP5G2
ATP synthase H+
transporting,
F0, C2
67942 −1.09 −1.03 1.10 −1.10 −1.10 −1.33 −1.26∗∗
ATP5G3
ATP synthase H+
transporting,
F0, C3
228033 1.62 1.48 −1.01 1.05 −1.10 −1.12 −1.10∗∗
ATP5H
ATP synthase H+
transporting,
F0, D
71679 1.18 1.10 1.05 1.06 −1.01 −1.30 −1.38∗∗
ATP5I
ATP synthase H+
transporting,
F0, E
11958 −1.01 −1.45 −1.03 1.10 1.17 −1.38 −1.50∗∗
ATP5J
ATP synthase H+
transporting,
F0, F6
11957 −1.20 1.44 −1.04 −1.07 −1.14 −1.25 −1.35∗∗
ATP5J2 ATP synthase H+
transporting,F0, F2 57423 2.38 −1.56 −1.05 −1.09 1.03 −1.29 −1.35∗∗
ATP5L
ATP synthase H+
transporting,
F0, G
27425 1.58 1.21 −1.02 1.00 −1.05 −1.33 −1.30∗∗
ATP5O
ATP synthase H+
transporting,
F1, O
28080 1.12 1.16 1.06 1.22 −1.03 −1.33 −1.31∗∗
ATP6V0B
ATPase, H+
transporting,
V0 unit b
114143 −1.37 −1.25 1.03 −1.09 1.05 −1.22 −1.20∗∗
ATP6V1F
ATPase, H+
transporting,
V1 unit F
66144 −1.18 1.23 1.00 1.05 1.01 −1.33 −1.28∗∗
COX4I1
cytochrome c
oxidase unit
IV isoform 1
12857 1.14 1.15 1.02 1.03 −1.15 −1.19 −1.16∗∗
COX5A cytochrome c
oxidase unit Va 12858 1.25 1.12 −1.02 1.09 −1.13 −1.26 −1.33∗∗
COX5B cytochrome c
oxidase unit Vb 12859 1.19 1.33 1.09 1.08 −1.27 −1.27 −1.35∗∗
COX6B1 cytochrome c
oxidase unit VIb1 110323 1.32 1.39 −1.01 1.10∗ −1.12 −1.25 −1.19∗
COX6C cytochrome c
oxidase unit VIc 12864 1.62 −1.23 1.03 −1.05 1.21 −1.22 −1.25∗∗
COX7A2 cytochrome c
oxidase unit VIIa 2 12866 −1.68 −1.08 −1.04 −1.04 −1.57 −1.39 −1.37∗∗
COX7C cytochrome c
oxidase unit VIIc 12867 1.22 1.32 −1.03 −1.28∗ −1.05 −1.23 −1.19∗∗
COX8A cytochrome c
oxidase unit 8A 12868 1.34 1.34 1.02 1.04 1.07 −1.23 −1.13∗PPAR Research 13
Table 9: Continued.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
NDUFA1 NADH dehydrogenase 1
alpha1 54405 −1.19 1.13 −1.03 −1.11 −1.25 −1.31 −1.49∗∗
NDUFA2 NADH dehydrogenase 1
alpha 2 17991 1.06 1.18 1.04 1.04 −1.06 −1.26 −1.33∗∗
NDUFA3 NADH dehydrogenase 1
alpha 3 66091 1.60 1.60 1.06 1.16∗ −1.06 −1.37 −1.30∗∗
NDUFA4 NADH dehydrogenase 1
alpha 4 17992 1.02 2.46 −1.00 1.01 3.16 −1.12 −1.11∗∗
NDUFA5 NADH dehydrogenase 1
alpha 5 68202 1.41 1.26 1.10 1.11 −1.07 −1.55 −1.73∗∗
NDUFA6 NADH dehydrogenase 1
alpha 6 67130 1.10 1.06 1.02 −1.04 −1.02 −1.34 −1.29∗∗
NDUFA7 NADH dehydrogenase 1
alpha 7 66416 −1.14 −1.01 1.09 1.12 −1.17 −1.45 −1.38∗∗
NDUFA8 NADH dehydrogenase 1
alpha 8 68375 1.14 1.33 1.00 1.09 1.05 −1.29 −1.18∗
NDUFA12 NADH dehydrogenase 1
alpha12 66414 1.47 1.16 −1.03 1.06 1.06 −1.51 −1.40∗∗
NDUFA13 NADH dehydrogenase 1
alpha13 67184 −1.12 −1.16 −1.03 −1.03 −1.08 −1.26 −1.28∗∗
NDUFA9 NADH dehydrogenase 1
alpha 9 66108 1.18 1.07 1.02 −1.01 −1.09 −1.20 −1.19∗∗
NDUFAB1 NADH dehydrogenase 1,
alpha/beta 1 70316 1.56 1.19 1.05 1.23∗ −1.07 −1.31 −1.44∗
NDUFB2 NADH dehydrogenase 1
beta 2 68198 −2.31 −3.32 1.04 1.11 1.49 −1.31 −1.35∗∗
NDUFB3 NADH dehydrogenase 1
beta 3 66495 1.55 1.93 1.09 1.19 1.05 −1.41 −1.32∗∗
NDUFB4 NADH dehydrogenase 1
beta 4 68194 −1.03 1.17 −1.01 1.06 −1.13 −1.45 −1.46∗∗
NDUFB5 NADH dehydrogenase 1
beta 5 66046 1.21 1.13 1.08 1.03 1.05 −1.28 −1.41∗∗
NDUFB6 NADH dehydrogenase 1
beta 6, 230075 1.32 −1.03 1.04 1.19 −1.02 −1.38 −1.36∗∗
NDUFB7 NADH dehydrogenase 1
beta 7, 66916 1.02 1.14 1.04 1.11 −1.11 −1.40 −1.29∗∗
NDUFB9 NADH dehydrogenase 1
beta 9, 66218 1.19 1.01 1.05 1.01 −1.08 −1.22 −1.25∗∗
NDUFB11 NADH dehydrogenase 1
beta 11 104130 −1.29 1.05 1.05 1.06 −1.00 −1.26 −1.23∗∗
NDUFC1 NADH dehydrogenase 1
unknown 1 66377 −1.28 1.84 1.07 1.21∗ 1.17 −1.28 −1.37∗∗
NDUFC2 NADH dehydrogenase 1
unknown, 2 68197 −1.02 1.13 1.06 1.06 −1.13 −1.37 −1.33∗∗
NDUFS4 NADH dehydrogenase
Fe-S protein 4 17993 1.51 1.21 1.12 −1.12 1.07 −1.41 −1.40∗∗
NDUFS5 NADH dehydrogenase
Fe-S protein 5 595136 1.16 1.13 −1.01 1.08 1.02 −1.37 −1.44∗∗
NDUFS7 NADH dehydrogenase
Fe-S protein 7 75406 1.09 1.40 1.09 1.13∗ 1.07 −1.28 −1.1514 PPAR Research
Table 9: Continued.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
NDUFS6 NADH dehydrogenase
Fe-S protein 6 407785 −1.32 1.06 −1.01 1.02 −1.14 −1.30 −1.32∗∗
NDUFV2 NADH dehydrogenase
ﬂavoprotein 2 72900 1.38 1.09 1.06 1.07 −1.02 −1.24 −1.24∗∗
NDUFV3 NADH dehydrogenase
ﬂavoprotein 3, 78330 1.12 1.16 −1.03 −1.01 −1.14 −1.35 −1.39∗∗
UCRC ubiquinol-cytochrome c
reductase 66152 1.58 1.26 1.10 1.27 1.07 −1.40 −1.27∗∗
UHRF1BP1 UHRF1 binding
protein 1 224648 −1.03 1.36 −1.08 1.06 1.15 1.23 1.15∗∗
UQCR ubiquinol-cytochrome
cr e d u c t a s e 66594 1.26 1.40 1.04 1.14∗ 1.09 −1.28 −1.19∗
UQCRC2 ubiquinol-cytochrome
c reductase CP II 67003 1.09 1.17 1.07 1.13 −1.04 −1.11 −1.27∗
UQCRQ ubiquinol-cytochrome
c reductase 3 unit 7 22272 1.01 1.08 1.07 1.12∗ −1.07 −1.18 −1.21∗∗
1From Rosen et al. [1], ∗Signiﬁcantly diﬀerent than control (P ≤ .03),∗∗Signiﬁcantly diﬀerent than control (P ≤ .0025).
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Acetyl-coenzyme a acyltransferase 1 [ACAA1, entrez no. 113868]
Acyl-coenzyme a oxidase 1, palmitoy [ACOX1, entrez no. 11430]
Cytochrome P450, family 4, subfamily a, polypeptide 14 [CYP4A14, entrez no. 13119]
Enoyl-coenzyme a, hydratase [EHHADH, entrez no. 74147]
Fatty acid binding protein 1, liver [FABP1, entrez no. 14080]
Hydroxyacyl-coenzyme a dehydrogenase trifunctional protein, α subunit [HADHA, entrez no. 97212]
Hydroxyacyl-coenzyme a dehydrogenase trifunctional protein, β subunit [HADHB, entrez no. 231086]
Hydroxysteroid 17-β dehydrogenase 4 [HSD17B4, entrez no. 15488]
Malic enzyme 1, NADP+−dependent, cytosolic [ME1, entrez no. 17436]
Pyruvate dehydrogenase kinase, isozyme 4 [PDK4, entrez no. 27273]
Acyl-coenzyme a dehydrogenase, long chain [ACADL, entrez no. 11363]
Figure 2: Expression of a group of well characterized markers of PPARα transactivation in WT and Null mice. The response to PFOS in
WT mice was less robust than that previously observed for either PFOA or Wy14,643. Red or green correspond to average up- or down-
regulation, respectively.PPAR Research 15
Table 10: Average fold change for genes related to ribosome biogenesis following a seven-day exposure to Wy-14,6431,P F O A 1,o rP F O Si n
wild-type and PPARα-null male mice.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
MRPL12 mitochondrial
ribosomal protein L12 56282 −1.16 1.25 1.07 1.14∗ −1.16 −1.18 −1.12∗
MRPL13 mitochondrial
ribosomal protein L13 68537 1.32 1.33 1.12 1.35∗ 1.01 −1.21 −1.42∗∗
MRPL17 mitochondrial
ribosomal protein L17 27397 1.68 1.76 1.10 1.43∗∗ 1.13 −1.13 1.09
MRPL23 mitochondrial
ribosomal protein L23 19935 −1.14 −1.04 −1.00 1.10 1.09 −1.38 −1.20∗
MRPL33 mitochondrial
ribosomal protein L33 66845 1.22 1.26 1.07 1.05 1.04 −1.29 −1.28∗∗
MRPS12 mitochondrial
ribosomal protein S12 24030 −1.24 1.18 1.05 1.12 1.02 −1.27 −1.15
MRPS18A mitochondrial
ribosomal protein S18A 68565 −1.46 1.34 1.04 1.28∗ 1.60 −1.19 −1.06
RPL10 ribosomal protein
L10 110954 −1.15 −1.21 1.02 1.03 1.07 −1.10 −1.02
RPL10A ribosomal protein
L10A 19896 −1.11 1.10 1.03 1.05 1.00 −1.07 1.01
RPL11 ribosomal protein
L11 67025 1.14 1.12 1.10 1.11∗ 1.15 −1.15 −1.09
RPL12 ribosomal protein
L12 269261 1.01 1.37 1.08 1.15∗ 1.11 −1.08 1.05
RPL13A ribosomal protein
L13a 22121 −1.14 1.03 1.07 1.12∗ −1.17 −1.15 −1.10
RPL14 ribosomal protein
L14 67115 −1.28 −1.06 1.15 1.23∗∗ −1.13 −1.18 −1.22∗
RPL17 ribosomal protein
L17 319195 −1.27 1.15 1.03 1.12 −1.52 −1.10 −1.09
RPL18 ribosomal protein
L18 19899 −1.11 1.28 1.04 1.07∗ 1.19 −1.27 −1.09∗
RPL18A ribosomal protein
L18a 76808 1.65 −1.37 1.04 1.11∗ 1.08 −1.15 −1.02
RPL19 ribosomal protein
L19 19921 1.22 1.23 1.01 1.05 1.07 −1.11 −1.03
RPL21 ribosomal protein
L21 19933 2.00 1.55 1.03 1.09 1.18 −1.20 −1.18
RPL22 ribosomal protein
L22 19934 1.17 1.45 1.06 1.29∗∗ 1.08 −1.25 −1.14∗
RPL23 ribosomal protein
L23 65019 −1.07 1.35 1.06 1.06 1.22 −1.24 −1.16
RPL24 ribosomal protein
L24 68193 −1.13 1.07 1.06 1.09∗ −1.00 −1.19 −1.11∗
RPL26 ribosomal protein
L26 19941 1.04 1.22 1.03 1.03 1.07 −1.22 −1.18∗∗
RPL27 ribosomal protein
L27 19942 1.04 −1.01 1.08 1.38∗∗ 1.06 −1.25 −1.40∗
RPL27A ribosomal protein
L27a 26451 −1.07 1.07 −1.00 1.17 1.26 −1.17 −1.09
RPL28 ribosomal protein
L28 19943 1.29 1.04 1.01 1.11∗ 1.67 −1.22 −1.10
RPL29 ribosomal protein
L29 19944 1.16 −1.30 1.04 1.09 1.08 −1.23 −1.1716 PPAR Research
Table 10: Continued.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
RPL3 ribosomal protein
L3 27367 −1.00 −1.14 1.01 1.09 −1.01 −1.03 1.06
RPL30 ribosomal protein
L30 19946 −1.15 −1.07 1.02 −1.21 −1.04 −1.29 −1.23∗∗
RPL31 ribosomal protein
L31 114641 1.11 1.37 1.09 1.05 1.29 −1.18 −1.12∗
RPL32 ribosomal protein
L32 19951 1.06 1.11 1.02 1.12∗ 1.08 −1.16 −1.03
RPL34 ribosomal protein
L34 68436 −1.26 1.16 −1.07 1.05 −1.04 −1.22 −1.31∗∗
RPL35 ribosomal protein
L35 66489 −1.03 1.15 1.13 1.26∗∗ 1.04 −1.17 −1.11
RPL36 ribosomal protein
L36 54217 −1.07 1.12 1.09 1.23∗ 1.07 −1.27 −1.20∗
RPL37 ribosomal protein
L37 67281 −1.16 −1.18 1.04 1.27∗ 1.17 −1.19 −1.10∗∗
RPL37A ribosomal protein
L37a 19981 −1.15 −1.09 1.03 1.16 −1.12 −1.22 −1.19∗
RPL38 ribosomal protein
L38 67671 −1.17 1.14 −1.01 1.06 −1.03 −1.18 −1.10
RPL39 ribosomal protein
L39 67248 1.04 1.02 1.06 1.13∗ 1.07 −1.18 −1.16∗∗
RPL4 ribosomal protein
L4 67891 1.16 1.43 1.03 1.03 1.32 1.03 1.04
RPL41 ribosomal protein
L41 67945 −1.06 1.14 1.05 1.06 −1.13 −1.20 −1.26∗
RPL5 ribosomal protein
L5 19983 −1.21 1.02 1.24 1.09∗ −1.05 −1.05 −1.11
RPL6 ribosomal protein
L6 19988 1.01 −1.08 1.00 1.05 1.15 −1.05 1.03
RPL7A ribosomal protein
L7a 27176 −1.02 −1.11 1.01 1.01 −1.02 −1.07 1.01
RPL9 ribosomal protein
L9 20005 −1.35 −1.08 1.03 1.07 −1.11 −1.19 −1.12∗
RPS10 ribosomal protein
S10 67097 −1.02 1.02 1.05 1.07 1.00 −1.17 −1.12∗
RPS11 ribosomal protein
S11 27207 1.05 −1.74 −1.01 1.11 1.06 −1.24 −1.14∗
RPS12 ribosomal protein
S12 20042 1.16 1.22 1.11 1.19 1.22 −1.21 −1.12
RPS13 ribosomal protein
S13 68052 −1.03 1.10 1.07 1.22∗ 1.11 −1.27 −1.22∗
RPS14 ribosomal protein
S14 20044 −1.03 1.19 1.05 1.11∗ 1.01 −1.17 −1.11∗∗
RPS15A ribosomal protein
S15a 267019 −1.05 1.05 1.02 1.12 1.02 −1.14 −1.20
RPS16 ribosomal protein
S16 20055 −1.09 1.05 1.05 1.07 −1.02 −1.12 −1.07
RPS17 ribosomal protein
S17 20068 1.00 1.16 1.04 −1.19∗ 1.01 −1.19 −1.15∗
RPS19 ribosomal protein
S19 20085 −1.07 1.23 1.08 1.19∗∗ −1.00 −1.14 −1.05
RPS2 ribosomal protein
S2 16898 −1.09 1.02 1.04 1.02 −1.16 −1.03 1.04PPAR Research 17
Table 10: Continued.
WT Null
Symbol Gene name Entrez no. Wy14,643
50mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
PFOA
3mg/kg
PFOS
3mg/kg
PFOS
10mg/kg
RPS20 ribosomal protein
S20 67427 −1.40 1.21 1.04 1.15 1.25 −1.11 −1.13
RPS21 ribosomal protein
S21 66481 1.11 −1.32 1.15 1.38 1.39 −1.32 −1.25∗∗
RPS23 ribosomal protein
S23 66475 1.01 1.04 −1.00 1.04 1.09 −1.21 −1.10∗
RPS24 ribosomal protein
S24 20088 1.58 1.62 1.11 −1.29∗ 1.75 −1.16 −1.19∗∗
RPS25 ribosomal protein
S25 75617 −1.23 1.01 1.09 1.13∗ −1.02 −1.30 −1.17∗
RPS26 ribosomal protein
S26 27370 1.32 1.30 1.04 1.16∗ 1.14 −1.20 −1.08
RPS27A ribosomal protein
S27a 78294 1.05 −1.05 −1.00 1.02 1.09 −1.08 −1.05
RPS27L ribosomal protein
S27-like 67941 1.72 1.28 1.07 1.14∗ 1.19 −1.18 −1.17∗
RPS28 ribosomal protein
S28 54127 −1.19 −1.03 1.03 1.06 −1.05 −1.28 −1.17∗
RPS29 ribosomal protein
S29 20090 −1.26 −1.05 −1.02 1.01 −1.03 −1.19 −1.20∗∗
RPS3 ribosomal protein
S3 27050 −1.04 1.29 1.03 1.20∗ −2.88 −1.11 −1.06
RPS3A ribosomal protein
S3A 544977 −1.18 −1.07 1.02 −1.01 −1.05 −1.10 −1.03
RPS5 ribosomal protein
S5 20103 −1.16 1.18 1.06 1.09∗ −1.02 −1.13 −1.00
RPS6 ribosomal protein
S6 20104 −1.20 −1.02 −1.20 1.06 −1.02 −1.14 −1.06∗
RPS8 ribosomal protein
S8 20116 1.19 −1.05 1.07 1.13∗ 1.04 −1.29 −1.13
RPS9 ribosomal protein
S9 76846 −1.39 1.30 1.05 1.07 1.05 −1.08 −1.04
1From Rosen et al. (2008), ∗Signiﬁcantly diﬀerent than control (P ≤ .03),
∗∗Signiﬁcantly diﬀerent from control (P ≤ .0025).
normalized using Robust Multichip Average methodol-
ogy (RMA Express, ver. 1.0). Prior to statistical analysis,
microarray data were ﬁltered to remove probe sets with
weak or no signal. Data were analyzed for each strain
using a one-way ANOVA across dose (Proc GLM, SAS
ver. 9.1, Cary, NC). Individual treatment contrasts were
evaluated using a pairwise t-test of the least square means.
Signiﬁcant probe sets (P ≤ .0025) were evaluated for
relevancetobiologicalpathwayandfunctionusingIngenuity
Pathway Analysis software (http://analysis.ingenuity.com/)
and DAVID functional annotation software [37]. Duplicate
probe sets were resolved using minimum P-value. Data were
further evaluated without statistical ﬁltering using Gene
Set Enrichment Analysis (GSEA) software available from
the Broad Institute [38]. Hierarchical clustering and heat
maps were generated using Eisen Lab Cluster and Treeview
software (version 2.11).
3. Results
3.1. Necropsy and Histopathology. Liver weight increased at
the highest dose of PFOS in both WT and Null animals
(Table 1). Histological changes were also noted. Vacuole
formation was observed in tissue sections from treated
WT mice, as well as in sections from control and treated
Null mice (Figure 1). The origin of these vacuoles was not
fully apparent. Kudo and Kawashima [28] reported that
chronic exposure to PFOA can induce fatty liver in mice
due to altered triglyceride transport; hence, vacuolization
in the current study may be the result of similar changes
in WT mice. In Null mice, vacuole formation may also
reﬂectincreasedtriglycerideretentionduetoreducedhepatic
fatty acid catabolism. Furthermore, our group has suggested
that a certain degree of vacuolization may be unrelated to
triglyceride retention in PFOA-exposed Null mice [29]. It18 PPAR Research
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Figure 3: Functional categories of genes modiﬁed by PFOS in WT and Null mice. In WT mice, PFOS altered the expression of genes related
to a variety of PPARα-regulated functions including lipid metabolism, peroxisome biogenesis, proteasome activation, and the inﬂammatory
response. Genes aﬀected in both WT and Null mice consisted of transcripts related to lipid metabolism, inﬂammation, and xenobiotic
metabolism. Several categories of genes were uniquely regulated by PFOS in Null mice including up-regulation of genes in the cholesterol
biosynthesis pathway as well as modest down-regulation of genes associated with oxidative phosphorylation and ribosome biogenesis. Red
or green corresponds to average up- or down- regulation, respectively.
is possible therefore, that hepatic vacuolization might be
associated with the liver weight increase observed in treated
Null animals.
3.2. Gene Proﬁling. Based on the number of genes signiﬁ-
cantly altered by PFOS (P ≤ .0025), gene expression changes
in WT mice were more evident at the higher dose of PFOS
compared to the lower dose. This was in contrast to changes
observed in Null mice where the number of transcripts
inﬂuenced by PFOS was similar across either dose group.
Hence, certain PPARα-independent eﬀects were found to be
robust in Null mice even at the lowest dose of PFOS. This
pattern of gene expression also varied from that previously
observed by our group for PFOA where only moderate
changes were found in Null mice compared to WT animals
[1](Table 2).Byexaminingtheexpressionofasmallgroupof
well characterized markers of PPARα transactivation, PFOS
also appeared to be a less robust activator of murine PPARα
than PFOA (Figure 2), a conclusion formerly reported by
others [18, 39, 40].
In WT mice, PFOS modiﬁed the expression of genes
related to a variety of PPARα-regulated functions including
lipidmetabolism,peroxisomebiogenesis,proteasomeactiva-
tion, and the inﬂammatory response. Genes aﬀected in both
WT and Null mice consisted of transcripts related to lipid
metabolism, inﬂammation, and xenobiotic metabolism,
including the CAR inducible gene, Cyp2b10. It should bePPAR Research 19
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Microarray RT-PCR
1
Cytochrome P450, 2b10, entrez no. 13088 (Cyp2b10)
Cytochrome P450, 4a14, entrez no. 13119 (Cyp4a14)
Cytochrome P450, 7a1, entrez no. 13122 (Cyp7a1)
Lanosterol synthase, entrez no. 16987 (Lss)
NADH dehydrogenase 1a, subcomplex, 5, entrez no. 68202 (Ndufa5)
Nuclear factor erythroid-derived 2-like 2, entrez no. 18024 (Nrf2)
PPARγ coactivaor 1a, entrez no. 19017 (Pgc-1a)
Sterol regulatory element binding transcription factor 2, entrez no. 20788 (Srebf2)
Figure 4: Microarray and Real-time PCR analysis of selected genes. Data from both assays were in close agreement. Small changes in Ndufa5
expression, a gene which encodes for a subunit of mitochondrial respiratory chain complex I, could not be conﬁrmed by RT-PCR. As
predicted based on microarray analysis, PFOS did not appear to up-regulate the expression of Srebf2, Ppargc1a (Pgc-1a),o rNfe2l2 (Nrf2)
in WT or Null mice. Red or green correspond to average up- or down- regulation, respectively.
stressed, however, that those changes associated with the
inﬂammatory response in Null mice were modest and were
only apparent within the context of similar but more robust
c h a n g e si nW Tm i c e .S e v e r a lc a t e g o r i e so fg e n e sw e r ea l s o
uniquely regulated in Null mice by PFOS including up-
regulation of genes in the cholesterol biosynthesis pathway,
along with modest down-regulation of genes (<1.5 fold
change) associated with oxidative phosphorylation and
ribosome biogenesis (Figure 3). Changes related to ribosome
biogenesis were particularly subtle and were identiﬁed by
the computational method provided by GSEA using the
complete set of expressed genes without statistical ﬁltering.
This approach allowed for an a priori set of genes to
be evaluated for signiﬁcant enrichment without regard for
the statistical signiﬁcance of individual genes. Among the
changes uniquely induced by PFOS in Null mice was up-
regulation of Cyp7a1, an important gene related to bile
acid/cholesterol homeostasis. Data for individual genes are
provided in Tables 3−10.
3.3. PCR Conﬁrmation. The results from real-time RT-
PCR analysis of selected genes are summarized, along with
the corresponding results from the microarray analysis, in
Figure 4. The data from both assays were in close agreement.
It should be pointed out that while up-regulation of Cyp2b10
was conﬁrmed in treated WT and Null mice, it remained
a low copy number transcript in these animals. Down-
regulation of Ndufa5, a gene which encodes for a subunit
of mitochondrial respiratory chain complex I, could not
be conﬁrmed in treated Null mice. This result, however,
was not surprising because the changes associated with
oxidative phosphorylation in the current study were small
and, therefore, diﬃculttodetectgiventhetechnicalvariation
normally associated with real-time PCR. As predicted based
on the microarray results, PFOS did not appear to up-
regulate the expression of Srebf2, Ppargc1a,o rNfe2l2 (Nrf2)
in either WT or Null mice.
4. Discussion
Inthecurrentstudy,exposuretoPFOSinducedbothPPARα-
dependent and PPARα-independent eﬀects in the murine
liver. In WT mice, the observed changes were primarily
indicative of a weak PPARα activator. As such, PFOS induced
hepatomegaly and altered the expression of genes related to
a number of biological functions known to be regulated by
PPARα including lipid metabolism, peroxisome biogenesis,
proteasome activation, and the inﬂammatory response [41–
45]. These data are also in agreement with previous studies
done in either the adult or fetal rodent [46–50]. Among
those eﬀects found to be independent of PPARα was altered
expression of genes associated with xenobiotic metabolism,
includingup-regulationoftheCARinduciblegene,Cyp2b10.
Such changes, which were found in both WT and Null mice,
were also consistent with results previously reported by our
group for PFOA [32, 33]. Although xenobiotic metabolism
c a nb er e g u l a t e db ym o r et h a no n en u c l e a rr e c e p t o r[ 51],
the ability of PFOA or perﬂuorodecanoic acid (PFDA) to
activate CAR has been demonstrated in experiments using
multiple receptor-null mouse models [31]; therefore, it is
likely that PFOS functions as an activator of CAR as well.
Additional PPARα-unrelated eﬀects were further indicated20 PPAR Research
by regulation of a group of genes associated with lipid
metabolism and inﬂammation in both WT and Null mice.
As suggested for mice exposed to PFOA [1, 33], such
changes could be due to activation of either PPARγ and/or
PPARβ/δ. Indeed, studies done using transient transfection
reporter cell assays indicate that PFOS and PFOA have the
potential to modestly activate other PPAR isotypes. [39, 40].
Furthermore,peroxisomeproliferation,ahallmarkofPPARα
transactivation, can also be induced in the rodent liver by
activating PPARγ and/or PPARβ/δ [52] ;h e n c e ,ad e g r e e
of functional overlap might be expected among the PPAR
isotypes. Particularly noteworthy were PPARα-independent
eﬀects that were unique to Null mice since they were not
previously observed in mice treated with PFOA [1, 33].
These included modiﬁed expression of genes associated
with ribosome biogenesis, oxidative phosphorylation, and
cholesterol biosynthesis. While activation of PPARα has
been linked to changes in cholesterol homeostasis [19]
and oxidative phosphorylation [53], it should be stressed
that such changes were not simply the result of targeted
disruption of PPARα because they were observed in treated
animals over and above those eﬀects which occurred in
Null controls. Moreover, in the current study, genes linked
to cholesterol biosynthesis were found to be up-regulated
in Null mice, an eﬀect that mirrored changes previously
reported in WT mice treated with the PPARα agonist, Wy
14,643 [1].
Recognition that PPAR ligands can induce “oﬀ-target”
eﬀects is not new (for review, see [54]). It is not clear,
however, whether the eﬀects described for Null mice in
the current study were the result of modiﬁed activity of
transcription regulators, which only became apparent in
the absence of PPARα signaling, or whether these changes
represent some other aspect of murine metabolism aﬀected
by PFOS. Of interest was up-regulation of Cyp7a1. This gene
encodes for an enzyme responsible for the rate limiting step
in the classical pathway of hepatic bile acid biosynthesis
a n di si m p o r t a n tf o rb i l ea c i d / c h o l e s t e r o lh o m e o s t a s i s[ 55].
While targeted disruption of PPARα does not appear to
alter basal levels of Cyp7a1 [56], PPARα agonists such as,
ﬁbratescanreducebothCyp7a1 geneexpressionandbileacid
biosynthesis in wild-type rodents [57] possibly by interfering
with promoter binding of HNF4 [58]. Regulation of Cyp7a1
is often associated with the liver X receptor (LXR) [59]b u t
it is tightly controlled by multiple pathways and may be
positively regulated by the pregnane X receptor (PXR) [60]
and the retinoid X receptor (RXR) as well [61]. While the
two LXR subtypes, LXRα and LXRβ, are lipogenic and play a
key role in regulating cholesterol homeostasis [62, 63], they
are not thought to be positive regulators of genes in the
cholesterol biosynthesis pathway [64].
Additional signaling pathways that may contribute to the
eﬀects observed in Null mice include pathways regulated
by Srebf2 (Srebp2) and PPARGC1α (PGC-1α). Srebf2 is
o n em e m b e ro fag r o u po fm e m b r a n e - b o u n dt r a n s c r i p t i o n
factors that play an important role in maintaining lipid
homeostasis. SREBF2 is best known for positively regulating
cholesterol synthesis in the liver and other tissues (Horton
et al., 1998). While decreased nuclear abundance of SREBP2
has been linked to increased hepatic PPARα activity in
rats [65], a PPARα-independent mechanism of action has
been suggested in mice as well which, in combination with
increased expression of CYP7a1, may paradoxically also
function via decreased SREBF2 signaling [66]. It should be
noted that transcript levels of Srebf2 were not aﬀected in the
current study nor was PFOS found to alter Srebf2 expression
in cultured chicken hepatocytes [67], although such changes
are not necessarily required for transcription factor regula-
tion. Rather than functioning as a transcription factor like
SREBP2, PPARGC-1α is a transcription coactivator that was
ﬁrst described as a moderator of PPARγ-induced adaptive
thermogenesis in brown adipose tissue [68]. PPARGC-1α is
now known to regulate various aspects of energy metabolism
in diﬀerent tissues by interacting with a host of transcription
factors,includingPPARα[69,70].CertainPPARligandshave
been shown to inhibit oxidative phosphorylation [71–74]
and Walters et al. [75] recently reported that high doses of
PFOA could modify mitochondrial function in rats via a
pathway involving PPARGC-1α. Unlike their results, how-
ever, PFOS did not induce a change in expression of Ppargc
-1α or its downstream target, Nrf2, in the current study.
Cellular regulation of metabolism, however, is complex and
there are a number of potentially interrelated signaling
pathways, including HNF4α [76]a n dT O R[ 77], that based
on their biological function could theoretically be linked to
the eﬀects observed in PFOS-treated Null mice. Given the
diversity of eﬀects observed in the current study, it is likely
that more than one signaling pathway is responsible for the
biological activity reported for PFOS.
Because certain eﬀe c t sw e r ef o u n do n l yi nN u l lm i c e ,
their relevance to the toxicity of PFOS is not clear. Although
the developmental toxicity of PFOS has been shown to
be independent of PPARα in murine neonates [34], it
has also been suggested that rather than causing primary
alterations to the murine transcriptome, PFOS may alter the
physicochemical properties of fetal lung surfactant as the
critical event related to toxicity in these animals [78–80]. It
should also be stressed that in Null animals the magnitude
of change found for certain eﬀects was small, hence, the
reported eﬀects in the current study were subtle. On the
other hand, these data serve to reinforce two recurring
themes regarding the biological activity of PFAAs. First, as
a class of compounds, the activity of PFAAs may be quite
variable. Diﬀerences exist among PFAAs with regard to chain
length and functional group which inﬂuence, not only the
elimination half-life of assorted PFAAs [4, 7] and their
ability to activate PPARα [18], but potentially their ability
to modify the function of other transcription regulators as
well.Second,thebiologicalactivityofPFAAsislikelytodiﬀer
from that observed for ﬁbrate pharmaceuticals, the most
commonly studied ligands of PPARα. While much has been
learned from studies using ﬁbrate-exposed PPARα-null and
PPARα-humanized mice regarding the relevance of chronic
PPARα activation to liver tumor formation in humans [22],
additional information concerning the biological activity of
speciﬁc PFAAs remains relevant for risk assessment.
In summary, PFOS is a PPARα agonist that is capable
of inducing a variety of PPARα-independent eﬀects in WTPPAR Research 21
and Null mice, although the toxicological relevance of these
changes is uncertain. A number of these eﬀects such as,
altered expression of genes involved in lipid metabolism,
inﬂammation, and xenobiotic metabolism were observed
in both WT and Null animals, and were consistent with
prior studies done with either PFOS or PFOA. Other
eﬀects involving genes associated with ribosome biogenesis,
oxidative phosphorylation, and cholesterol biosynthesis were
unique to Null mice and may represent targeted signaling
pathways not yet described for certain PFAAs.
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